Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
PLoS One. 2012;7(5):e36677. doi: 10.1371/journal.pone.0036677. Epub 2012 May 22.
Chance imbalance in baseline prognosis of a randomized controlled trial can lead to over or underestimation of treatment effects, particularly in trials with small sample sizes. Our study aimed to (1) evaluate the probability of imbalance in a binary prognostic factor (PF) between two treatment arms, (2) investigate the impact of prognostic imbalance on the estimation of a treatment effect, and (3) examine the effect of sample size (n) in relation to the first two objectives.
We simulated data from parallel-group trials evaluating a binary outcome by varying the risk of the outcome, effect of the treatment, power and prevalence of the PF, and n. Logistic regression models with and without adjustment for the PF were compared in terms of bias, standard error, coverage of confidence interval and statistical power.
For a PF with a prevalence of 0.5, the probability of a difference in the frequency of the PF≥5% reaches 0.42 with 125/arm. Ignoring a strong PF (relative risk = 5) leads to underestimating the strength of a moderate treatment effect, and the underestimate is independent of n when n is >50/arm. Adjusting for such PF increases statistical power. If the PF is weak (RR = 2), adjustment makes little difference in statistical inference. Conditional on a 5% imbalance of a powerful PF, adjustment reduces the likelihood of large bias. If an absolute measure of imbalance ≥5% is deemed important, including 1000 patients/arm provides sufficient protection against such an imbalance. Two thousand patients/arm may provide an adequate control against large random deviations in treatment effect estimation in the presence of a powerful PF.
The probability of prognostic imbalance in small trials can be substantial. Covariate adjustment improves estimation accuracy and statistical power, and hence should be performed when strong PFs are observed.
随机对照试验中基线预后的机会不平衡可能导致治疗效果的高估或低估,尤其是在样本量较小的试验中。我们的研究旨在:(1)评估两种治疗组之间二项预后因素(PF)的不平衡概率;(2)研究预后不平衡对治疗效果估计的影响;(3)考察样本量(n)与前两个目标的关系。
我们通过改变结局的风险、治疗效果、PF 的功效和流行率以及 n,模拟了评估二项结局的平行组试验的数据。比较了有和没有 PF 调整的逻辑回归模型在偏差、标准误、置信区间覆盖和统计功效方面的差异。
对于流行率为 0.5 的 PF,在 125/臂时,PF 频率差异≥5%的概率达到 0.42。忽略一个强 PF(相对风险=5)会导致对中度治疗效果的低估,且当 n >50/臂时,低估与 n 无关。调整 PF 会增加统计功效。如果 PF 较弱(RR=2),调整对统计推断影响不大。如果 PF 强大,条件为 5%的不平衡,调整会降低出现大偏差的可能性。如果认为 5%的不平衡是重要的,则纳入 1000 名患者/臂可以提供足够的保护,防止出现这种不平衡。在存在强大 PF 的情况下,纳入 2000 名患者/臂可能会对治疗效果估计的大随机偏差提供充分的控制。
小试验中预后不平衡的概率可能很大。协变量调整可以提高估计的准确性和统计功效,因此应在观察到强 PF 时进行。